Cargando…
Targeting of saporin to CD25-positive normal and neoplastic lymphocytes by an anti-saporin/anti-CD25 bispecific monoclonal antibody: in vitro evaluation.
This study has been designed to verify the specific toxicity of saporin, a type 1 ribosome-inactivating protein (RIP), with the same activity as ricin A chain, targeted by a bispecific monoclonal antibody (bimAb) recognising both the CD25 antigen and the RIP. The CD25 antigen is expressed by lymphoi...
Autores principales: | Tazzari, P. L., Zhang, S., Chen, Q., Sforzini, S., Bolognesi, A., Stirpe, F., Xie, H., Moretta, A., Ferrini, S. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1993
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968507/ https://www.ncbi.nlm.nih.gov/pubmed/8512810 |
Ejemplares similares
-
Preclinical studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumours.
por: Flavell, D. J., et al.
Publicado: (1995) -
Efficacy and safety of anti-CD45–saporin as conditioning agent for RAG deficiency
por: Castiello, Maria Carmina, et al.
Publicado: (2020) -
Comparison of the potency and therapeutic efficacy of the anti-CD7 immunotoxin HB2-saporin constructed with one or two saporin moieties per immunotoxin molecule.
por: Flavell, D. J., et al.
Publicado: (1997) -
Saporin-conjugated tetramers identify efficacious anti-HIV CD8+ T-cell specificities
por: Leitman, Ellen M., et al.
Publicado: (2017) -
High in Vitro Anti-Tumor Efficacy of Dimeric Rituximab/Saporin-S6 Immunotoxin
por: Bortolotti, Massimo, et al.
Publicado: (2016)